Development of a novel antimicrobial capable of selectively killing Shiga toxin-producing Escherichia coli

Research Project

Project/Area Number	21K15436
Research Category	Grant-in-Aid for Early-Career Scientists
Allocation Type	Multi-year Fund
Review Section	Basic Section 49050:Bacteriology-related
Research Institution	Jichi Medical University
Principal Investigator	ティティアナンパコーン・カネート自治医科大学, 医学部, ポスト・ドクター (20882806)
Project Period (FY)	2021-04-01 – 2023-03-31
Project Status	Granted (Fiscal Year 2021)
Budget Amount *help	¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000) Fiscal Year 2022: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000) Fiscal Year 2021: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
Keywords	EHEC / CRISPR-Cas13a / Bacteriophage
Outline of Research at the Start	We will establish the new therapy for specific killing of EHEC infection together with suppression of Shiga toxin expression by designing CRISPR-Cas13a that recognizes stx genes, synthesizing antibacterial capsids, and verifying the cytotoxic and therapeutic effect of antibacterial capsids .